Võsa Urmo, Kolde Raivo, Vilo Jaak, Metspalu Andres, Annilo Tarmo
Estonian Genome Center, University of Tartu, Riia 23, 51010, Tartu, Estonia.
Methods Mol Biol. 2014;1182:361-73. doi: 10.1007/978-1-4939-1062-5_28.
Differential microRNA (miRNA) expression profiling by high-throughput methods has generated a vast amount of information about the complex role of these small regulatory molecules in a broad spectrum of human diseases. However, the results of such studies are often inconsistent, mostly due to the lack of cross-platform standardization, ongoing discovery of novel miRNAs, and small sample size. Therefore, a critical and systematic analysis of all available information is essential for successful identification of the most relevant miRNAs. Meta-analysis approach allows integrating the results from several independent studies in order to achieve greater statistical power and estimate the variability between the studies. Here we describe as an example the use of a robust rank aggregation (RRA) method for identification of miRNA meta-signature in lung cancer. This method analyzes prioritized gene lists and finds commonly overlapping genes, which are ranked consistently better than expected by chance. An RRA approach not only helps to prioritize the putative targets for further experimental studies but also highlights the challenges related with the development of miRNA-based tests and emphasizes the need for rigorous evaluation of the results before proceeding to clinical trials.
通过高通量方法进行的差异微小RNA(miRNA)表达谱分析已经产生了大量关于这些小调节分子在广泛人类疾病中复杂作用的信息。然而,此类研究结果往往不一致,主要原因是缺乏跨平台标准化、新miRNA的不断发现以及样本量较小。因此,对所有可用信息进行关键且系统的分析对于成功鉴定最相关的miRNA至关重要。荟萃分析方法允许整合来自多个独立研究的结果,以获得更大的统计效力并估计研究之间的变异性。在此,我们以使用稳健秩聚合(RRA)方法鉴定肺癌中的miRNA元特征为例进行描述。该方法分析优先排序的基因列表并找到通常重叠的基因,这些基因的排名始终比随机预期的要好。RRA方法不仅有助于为进一步的实验研究确定假定靶点的优先级,还突出了与基于miRNA的检测方法开发相关的挑战,并强调在进行临床试验之前对结果进行严格评估的必要性。